Journal of Gastroenterology

, Volume 29, Issue 4, pp 479–485 | Cite as

High-Dose intraperitoneal aprotinin treatment of acute severe pancreatitis: A double-blind randomized multi-center trial

  • Rikard Berling
  • Sven Genell
  • Kjell Ohlsson
Article

Abstract

A multi-center double-blind trial was performed on 48 patients with severe acute pancreatitis. All patients were treated with intraperitoneal lavage. One group (n=22) was also treated with high doses of the protease inhibitor, aprotinin (Trasylol; Bayer AG, Leverkusen, Germany) administered intraperitoneally. Eight patients died, giving a total mortality of 16.6%. No difference was observed between the two groups. Altogether, 12 patients were operated on, corresponding to 25%. In the group not treated with aprotinin, 6 patients were operated on because of pancreatic necrosis, compared with none in the treated group. The difference was statistically significant. There were no significant differences between the two groups with regard to organ failure or other complications. It was concluded that aprotinin counteracts the development of pancreatic necrosis when given intraperitoneally in high doses to patients with severe acute pancreatitis, thus reducing the need for surgical intervention in these patients.

Key words

acute pancreatitis aprotinin Trasylol pancreatic necrosis protease inhibitors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Glazer G. Contentious issues in acute pancreatitis. In: Glazer G, Ranson JHC (ed), Acute pancreatitis. Experimental and clinical aspects of pathogenesis and management. London: Baillére Tindall, 1988;1–36.Google Scholar
  2. 2.
    Chiari H. Über die Selbstverdaung des menshlichen Pankreas. Z Helik 1896;17:69–96.Google Scholar
  3. 3.
    Geokas MC, Rinderknecht H. Free proteolytic enzymes in pancreatic juice of patients with acute pancreatitis. Am J Dig Dis 1974;19:591–598.CrossRefPubMedGoogle Scholar
  4. 4.
    Rao KN, Tuma J, Lombardi B. Acute hemorrhagic pancreatic necrosis in mice: Intraparenchymal activation of zymogens and other enzyme changes in pancreas and serum. Gastroenterology 1976;70:720–726.PubMedGoogle Scholar
  5. 5.
    Yamaguchi H, Kimura T, Mimura K, Nawata H. Activation of proteases in cerulein-induced pancreatitis. Pancreas 1989:4:565–571.PubMedGoogle Scholar
  6. 6.
    Ohlsson K, Olsson R Björk P, et al. Local administration of human pancreatic secretory trypsin inhibitor prevents the development of experimental acute pancreatitis in rats and dogs. Scand J Gastroenterol 1989;24:693–704.PubMedGoogle Scholar
  7. 7.
    Hirano T, Manabe T, Tobe T. Protection by gabexate mesilate (FOY) of the exocrine pancreas in rats with acute pancreatitis induced by a supramaximal dose of caerulein. J Gastroenterol Hepatol 1991;6:260–264.PubMedGoogle Scholar
  8. 8.
    Fric P, Slaby J, Kasafirek E, et al. Effective peritoneal therapy of acute pancreatitis in the rat with glutaryl-trialanin-ethylamide: A novel inhibitor of pancreatic elastase. Gut 1992;33:701–706.PubMedGoogle Scholar
  9. 9.
    Trapnell JE, Rigby CC, Talbot CH, Duncan EHL. A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg 1974;61:177–182.PubMedGoogle Scholar
  10. 10.
    Imrie CW, Benjamin IS, Ferguson JC, et al. A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978;65:337–341.PubMedGoogle Scholar
  11. 11.
    Cox AG, M.R.C., Multicenter trial of glucagon and aprotinin. Lancet 1977;II:632–635.Google Scholar
  12. 12.
    Medical Research Council Multicentre Trial. Morbidity of acute pancreatitis: The effect of aprotinin and glucagon. Gut 1980;21:334–339.Google Scholar
  13. 13.
    Balldin G, Borgström A, Genell S, Ohlsson K. The effect of peritoneal lavage and aprotinin in the treatment of severe acute pancreatitis. Res Exp Med 1983;183:203–213.CrossRefGoogle Scholar
  14. 14.
    Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236–261.PubMedGoogle Scholar
  15. 15.
    Lasson Å, Ohlsson K. An in vitro study of the influence of plasma protease inhibitors and approtinin on trypsin-induced C3 cleavage in human serum. Biochim Biophys Acta 1982;709:227–233.PubMedGoogle Scholar
  16. 16.
    Lasson Å, Dittmann B, Ohlsson K. Influence of plasma proteinase inhibitors and aprotinin on trypsin-induced bradykinin release in vitro in man. Hoppe-Seyler's Z Physiolog Chem 1983;364:1315–1322.Google Scholar
  17. 17.
    Balldin G, Lasson Å, Ohlsson K. Aprotinin turnover studies in dog and man with severe acute pancreatitis. Hoppe-Seyler's Z Physiol Chem 1984;365:1417–1423.PubMedGoogle Scholar
  18. 18.
    Mancini G, Carbonara AO, Heremans JF. Immunochemical quantification of antigens by single radial immunodiffusion. Immunochemistry 1965;2:235–254.CrossRefPubMedGoogle Scholar
  19. 19.
    Ranson JHC, Rifkind KM, Roses DF, et al. Prognostic signs and the role of operation management in acute pancreatitis. Surg Gynecol Obstet 1974;139:69–81.PubMedGoogle Scholar
  20. 20.
    Fry DE. Diagnosis and epidemiology of multiple organ failure. In: Deitch EA (ed) Multiple organ failure: Pathophysiology and basic concepts of therapy. New York: Thieme Medical, 1990;13–25.Google Scholar
  21. 21.
    ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644–1655.Google Scholar
  22. 22.
    Ranson JHC, Rifkind KM, Turner JW. Prognostic signs and nonoperative peritoneal lavage in acute pancreatitis. Surg Gynecol Obstet 1976;143:209–219.PubMedGoogle Scholar
  23. 23.
    Büchler M, Uhl W, Berger HG. Acute pancreatitis: When and how to operate. Dig Dis 1992;10:354–362.PubMedGoogle Scholar
  24. 24.
    Bradley ELIII, Allen K. A prospective longitudinal study of observation versus surgical intervention in the management of necrotizing pancreatitis. Am J Surg 1991;161:19–25.CrossRefPubMedGoogle Scholar
  25. 25.
    Schröder T, Sainio V, Kivisaari L, et al. Pancreatic resection versus peritoneal lavage in acute necrotizing pancreatitis. Ann Surg 1991;214:663–666.PubMedGoogle Scholar
  26. 26.
    Baue AE. Multiple systems failure and circulatory support. Jpn J Surg 1983;13:69–85.PubMedGoogle Scholar
  27. 27.
    Baue AE. Recovery from multiple organ failure. Am J Surg 1985;149:420–421.PubMedGoogle Scholar
  28. 28.
    Ranson JHC, Spencer FC. The role of peritoneal lavage in severe acute pancreatitis. Ann Surg 1978;187:565–575.PubMedGoogle Scholar
  29. 29.
    Ranson JHC. Conservative surgical treatment of acute pancreatitis. World J Surg 1981;5:351–359.CrossRefPubMedGoogle Scholar
  30. 30.
    Mayer AD, M.J.M., Corfield AP, et al. Controlled clinical trial of peritoneal lavage for the treatment of severe acute pancreatitis. N Engl J Med 1985;312:399–404.PubMedGoogle Scholar
  31. 31.
    Ranson JHC, Berman RS. Long peritoneal lavage decreases pancreatic sepsis in acute pancreatitis. Ann Surg 1990;211:708–718.PubMedGoogle Scholar
  32. 32.
    Ohlsson K. Influence of the human pancreatic secretory trypsin inhibitor on trypsin-induced C3 and kininogen cleavage: An in vitro study. Scand J Gastroenterol 1986;21:18–20.Google Scholar
  33. 33.
    Funakoshi A, Miyasaka K, Jimi A, et al. Protective effect of human pancreatic secretory trypsin inhibitor on cerulein-induced acute pancreatitis in rats. Digestion 1992;52:145–151.PubMedGoogle Scholar
  34. 34.
    Ohnishi H, Kosuzume H, Ashida Y, et al. Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental pancreatitis. Dig Dis Sci 1984;29:26–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Valerrama R, Pérez-Mateo M, Navarro S, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion 1992;51:65–70.Google Scholar
  36. 36.
    Tanaka N, Tsuchiya R, Ishii K. Comparative clinical study of FOY and Trasylol in acute pancreatitis. Exp Biol Med 1979;120B:367–378.Google Scholar
  37. 37.
    Pederzoli P, Bassi C, Cavallini G, et al. The Italian multicenter trial on gabexate mesilate versus aprotinin in human acute pancreatitis (abstract from European Pancreatic Club meeting, Sept. 16–18, 1991). Digestion 1991;49(1):43.Google Scholar
  38. 38.
    Imrie CW, Mackenzie M. Effective aprotinin therapy in canine experimental bile-trypsin pancreatitis. Digestion 1981;22:32–38.PubMedGoogle Scholar
  39. 39.
    Rattner DW, Legermate DA, Lee MJ, et al. Early surgical debridement of symptomatic pancreatic necrosis is beneficial irrespective of infection. Am J Surg 1992;163:105–110.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Rikard Berling
    • 1
    • 3
  • Sven Genell
    • 2
    • 3
  • Kjell Ohlsson
    • 3
  1. 1.Department of Anaesthesiology Malmö General HospitalUniversity of LundMalmöSweden
  2. 2.Department of Surgery Malmö General HospitalUniversity of LundMalmöSweden
  3. 3.Department of Surgical Pathophysiology Malmö General HospitalUniversity of LundMalmöSweden

Personalised recommendations